Special Issue

Research Advances in Targeted Therapy for Facial Skin Diseases

Message from the Guest Editors

Facial skin diseases pose unique challenges due to the high visibility, complex anatomy, and psychosocial impact associated with the facial region. While conventional therapies offer symptomatic relief, they often lack specificity and may lead to undesirable effects. This Special Issue highlights the growing shift toward mechanism-driven, targeted interventions that improve efficacy while minimizing off-target actions. We invite contributions on the discovery and development of novel targeted therapeutics, including small molecules, biologics, peptides, nucleic acid-based agents, and topical nanocarriers designed for enhanced facial skin penetration. Submissions should emphasize target identification and validation—for instance, cytokines, signaling pathways, microbiome components, or neuroimmune interactions—and incorporate robust pharmacological characterization through binding, cellular, and tissue-level assays. Both original research and comprehensive review articles are invited for submission.

Guest Editors

Dr. Edileia Bagatin

Dr. Marco Alexandre Rocha

Dr. Diogo Pazzini Bomfim

Deadline for manuscript submissions

25 May 2026



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/258551

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

